Breast cancer is the most common type of cancer among women and is becoming more common every day. 

LETRA is used to treat certain types of breast cancer in postmenopausal women.

LETRA belongs to a group of medicines called aromatase inhibitors. It is a hormonal (or “endocrine”) breast cancer treatment with Letra. Growth of breast cancer is frequently stimulated by estrogens which are female sex hormones. LETRA reduces the amount of estrogen by blocking an enzyme (“aromatase”) involved in the production of estrogens and therefore may block the growth of breast cancer that needs estrogens to grow. 

LETRA does not cause changes in plasma levels of LH and FSH; does not affect the concentrations of TSH, T4 and T3 and, accordingly, the functions of the thyroid gland. 

Recommendations for use:

Letra is not used for diseases with negative hormone receptors. Letra is prescribed in the following cases:

• Early stages of invasive breast cancer, the cells of which have hormone receptors, in postmenopausal women, as adjuvant therapy.
• Early stage invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years as extended adjuvant therapy.
• Common hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy).
• Advanced breast cancer with the development of relapse or progression of the disease in postmenopausal women (natural or artificially induced) who received previous therapy with antiestrogens.